Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R&D across pharmaceuticals, materials science, and semiconductor industries.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

A low-carbon version of a triple combination pMDI inhaler indicated for adults with moderate-to-severe COPD has been approved by the MHRA.

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The clinical trial for the potential vaccine, VLA15, began in August 2022. Stage 3 trials got underway in late 2023, ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

NBCC: The company has successfully sold 446 residential units at Aspire Silicon City in Noida through an e-auction, generating Rs 1,468 crore in sales. Additionally, it will receive a marketing fee of ...

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...